Table 5.
Univariate analysis of PFS according to baseline characteristics and miRNAs.
| A | HR (95% CI) | p value |
|---|---|---|
| Age ≥58.5, n=61 | 1.02 (0.53-1.95) | 0.965 |
| Male Gender, n=90 | 1.05 (0.49-2.24) | 0.895 |
| Binet stage AB, n=91 | 0.80 (0.39-1.62) | 0.534 |
| ECOG 1, n=37 | 1.68 (0.89-3.28) | 0.126 |
| Unmutated IGHV, n=75 | 2.78 (1.21-6.41) | 0.012 |
| Cytogenetic abnormalities | ||
| Del(13q), n=54 | 0.61 (0.29-1.28) | 0.188 |
| Del(11q), n=24 | 1.79 (0.84-3.84) | 0.128 |
| Trisomy 12, n=9* | – | 0.039 |
| Lymphocyte count >71(G/L), n=61 | 2.70 (1.32-5.49) | 0.004 |
| β2 microglobulin >2 (mg/L), n=101 | 2.46 (0.59-10.25) | 0.202 |
| Treatment arm FCR, n=62 | 1.09 (0.57-2.09) | 0.802 |
| B | ||
| miR-15b high, n=58 | 1.02 (0.53-1.97) | 0.948 |
| miR-125b high, n=67 | 0.41 (0.19-0.89) | 0.021 |
| miR-181c high, n=29 | 0.49 (0.19-1.26) | 0.131 |
| miR-193b high, n=40 | 0.50 (0.22- 1.14) | 0.093 |
| miR-412 high, n=84 | 1.12 (0.55-2.29) | 0.754 |
Hazard ratios for PFS according to baseline characteristics (A) and miRNAs (B). *Indicates that 9 data are not available. No progression or progression event were registered in trisomy 12 group. The thresholds of the 5 miRNAs used to build the decision tree are presented. PFS, Progression free survival; HR, Hazard ratio; CI, Confidence interval.